RS56509B1 - Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline - Google Patents
Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiselineInfo
- Publication number
- RS56509B1 RS56509B1 RS20171063A RSP20171063A RS56509B1 RS 56509 B1 RS56509 B1 RS 56509B1 RS 20171063 A RS20171063 A RS 20171063A RS P20171063 A RSP20171063 A RS P20171063A RS 56509 B1 RS56509 B1 RS 56509B1
- Authority
- RS
- Serbia
- Prior art keywords
- dihydro
- compound
- salt
- benzoxazol
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| EP14793565.4A EP3066097B1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
| PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS56509B1 true RS56509B1 (sr) | 2018-02-28 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20171063A RS56509B1 (sr) | 2013-11-08 | 2014-11-05 | Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9926305B2 (https=) |
| EP (1) | EP3066097B1 (https=) |
| JP (1) | JP6446051B2 (https=) |
| KR (1) | KR102351418B1 (https=) |
| CN (1) | CN105658647B (https=) |
| AP (1) | AP2016009181A0 (https=) |
| AU (1) | AU2014345599B2 (https=) |
| BR (1) | BR112016010253A8 (https=) |
| CA (1) | CA2929780C (https=) |
| CL (1) | CL2016001096A1 (https=) |
| CY (1) | CY1119520T1 (https=) |
| DK (1) | DK3066097T3 (https=) |
| EA (1) | EA033132B1 (https=) |
| ES (1) | ES2645480T3 (https=) |
| HR (1) | HRP20171603T1 (https=) |
| HU (1) | HUE035021T2 (https=) |
| IL (1) | IL245407B (https=) |
| LT (1) | LT3066097T (https=) |
| MA (1) | MA39020A1 (https=) |
| ME (1) | ME02907B (https=) |
| MX (1) | MX366848B (https=) |
| MY (1) | MY190108A (https=) |
| NO (1) | NO3066097T3 (https=) |
| PH (1) | PH12016500853B1 (https=) |
| PL (1) | PL3066097T3 (https=) |
| PT (1) | PT3066097T (https=) |
| RS (1) | RS56509B1 (https=) |
| SA (1) | SA516371082B1 (https=) |
| SI (1) | SI3066097T1 (https=) |
| TN (1) | TN2016000170A1 (https=) |
| UA (1) | UA117686C2 (https=) |
| WO (1) | WO2015067652A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| WO2018197333A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2023194222A1 (en) * | 2022-04-05 | 2023-10-12 | Socpra Sciences Santé Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4175887B2 (ja) * | 2000-10-19 | 2008-11-05 | 日本化薬株式会社 | 新規血管狭窄治療剤または予防剤 |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| JP6549376B2 (ja) * | 2012-03-05 | 2019-07-24 | グラタク テクノロジーズ ピーティーワイ リミテッド | 栄養補助食品 |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| HK1224288A1 (zh) * | 2013-11-08 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
-
2014
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de not_active Ceased
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active Active
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
-
2017
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2603262T3 (es) | Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso | |
| CN117045653A (zh) | 与毒性醛相关的疾病和治疗 | |
| US20110257175A1 (en) | Selected Inhibitors of Protein Tyrosine Kinase Activity | |
| EP2875001A1 (en) | Nitrogenous heterocyclic derivatives and their application in drugs | |
| EP3773580A1 (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof | |
| JP2024150732A (ja) | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 | |
| RS56509B1 (sr) | Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline | |
| CA2929763A1 (en) | Substituted uracils as chymase inhibitors | |
| US20210053936A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| RS50563B (sr) | Ne-peptidni bradikinin antagonisti i njihove farmaceutske mešavine | |
| US20240317764A1 (en) | Salts and solid forms of a compound having apj receptor activity | |
| CN120774918A (zh) | 蛋白降解剂类化合物及其制备方法、药物组合物和应用 | |
| HK1222171B (zh) | 化合物的盐 | |
| CN120693332A (zh) | 一种钾离子竞争性酸阻滞剂的稳定无定形形式及其制备方法 | |
| DE102006039589A1 (de) | Aminoacyl-Prodrugs II | |
| CN116806150A (zh) | 新的自分泌运动因子抑制剂 | |
| NZ719532B2 (en) | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid | |
| CN104768927A (zh) | (3s,3s’)-4,4’-二硫烷二基双(3-氨基丁烷-1-磺酸)合l-赖氨酸的新的结晶相 | |
| CN116178435A (zh) | 一种1，-腈基取代核苷衍生物及其用途 | |
| HK40049475B (zh) | 一氧化氮释放第5型磷酸二酯酶抑制剂 | |
| CN119930520A (zh) | N-芳基吡唑类化合物及其药物组合物和应用 | |
| EP1604976A1 (en) | Nimesulide derivative method for its preparation and a pharmaceutical composition containing the same | |
| JP2012512206A (ja) | ４−（｛（４−カルボキシブチル）［２−（２−｛［４−（２−フェニルエチル）ベンジル］オキシ｝フェニル）エチル］−アミノ｝メチル）安息香酸の一水和物 | |
| WO2021036495A1 (zh) | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 | |
| JP2012512204A (ja) | ４−（｛（４−カルボキシブチル）［２−（２−｛［４−（２−フェニルエチル）ベンジル］オキシ｝フェニル）エチル］アミノ｝メチル）安息香酸の変態ｉ |